Pfizer Zithromax committee review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's Zithromax (azithromycin) one-day and three-day dosing regimens for otitis media treatment will be reviewed Nov. 7 by FDA's Anti-Infective Drugs Advisory Committee